Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-09-14
Tempus AI, Inc.
Tempus sells genomic diagnostics, clinical workflow software, and governed data products to healthcare providers and life sciences customers.
ai biotech healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Data Rights Meet Proof-Gated Healthcare AI
The upside case rests on governed clinical data, embedded workflows, and monitoring products becoming more valuable as AI gets cheaper. The open question is whether that strategic edge converts fast enough into recurring revenue and a better valuation mix.

Analysis

Thesis
Tempus can outgrow ordinary diagnostics if it turns governed clinical-genomic data, embedded oncology workflows, and expanding monitoring products into recurring higher-quality revenue; the upside is a mix shift from being valued mainly as a lab toward being valued as a regulated healthcare AI platform.
Last Economy Alignment
Cheaper AI makes Tempus’ governed data, regulated diagnostics, and workflow embed more valuable rather than obsolete, but reimbursement and approval gates slow full value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
This is mostly a quality-of-growth story. If Tempus proves its recent data license wins recur, closes and integrates Personalis well, and sells more reimbursed monitoring and embedded workflow actions, investors can keep valuing it above ordinary diagnostics peers. I do not need a pure software multiple; I need durable growth plus a better revenue mix.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is not product relevance but economic conversion. Tempus still has to prove that new data licenses become durable revenue, that newer assays and monitoring products clear evidence and reimbursement gates, and that Personalis integration improves mix without forcing renewed reliance on dilution or balance-sheet stretch.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.70
They control hard-to-get clinical and genomic data, lab-generated evidence, and workflow connections inside hospitals, so cheaper AI makes their dataset and tools more useful rather than less useful. The risk is that regulators, payers, or larger healthcare platforms slow the rollout before those advantages become durable revenue.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$65.79
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case